Sedivet (Canada)This page contains information on Sedivet for veterinary use.
The information provided typically includes the following:
- Sedivet Indications
- Warnings and cautions for Sedivet
- Direction and dosage information for Sedivet
SedivetThis treatment applies to the following species:
Sedative, pre-anaesthetic for horses.
Each mL contains 10 mg Romifidine in an aqueous solution. Non-medicinal ingredients (in alphabetical order): chlorocresol, sodium chloride and water for injection.
Sedivet® is indicated for use as a sedative to facilitate handling, examination, treatment and as a premedication agent prior to general anaesthesia. Induction of anaesthesia may be initiated 8-10 minutes after the administration of Sedivet®.
Sedivet® is a potent synthetic alpha-2-sympathomimetic agent. As with other agents in this class, there is dose dependent sedation associated with the tolerance of pain.
The sedative effect of Sedivet® is induced by a stimulation of presynaptic alpha-2-receptors in the central nervous system. Sedivet® possesses a strong affinity for those receptors. Lowering of the head is the first sign of sedation followed by lethargy, reduced sensitivity to environmental stimuli and immobility. The sleep-like state that results is dose dependent. Onset of sedation occurs in one to two minutes and lasts for 40 to 80 minutes.
When Sedivet® is given to intact, conscious or anaesthetized animals, a prolonged reduction in blood pressure and heart rate occurs. An initial transitory increase in blood pressure occurs followed by bradycardia and a sustained hypotensive response. A transient change in the conductivity of the cardiac muscle may occur as evidenced by a partial atrioventricular block. This may be prevented by the intravenous administration of atropine at 0.01 mg/kg, 3-5 minutes prior to the administration of Sedivet®.
In laboratory animals, both gastrointestinal and urinary systems are affected with gastric secretion and intestinal transit being inhibited.
In the horse, the urine is the principle route of excretion.
Dosage and Administration
Administer intravenously at a rate of 0.04 mg/kg to 0.10 mg/kg of body weight (0.4 to 1.0 mL/100 kg or 220 lbs) depending on the depth and duration of sedation required. Following injection, animals should be allowed to rest quietly until the full effect has been reached.
As a pre-anaesthetic, Sedivet® has been successfully used at the above dosages in anaesthesia protocols involving the muscle relaxant, guaifenesin, followed by thiamylal sodium, thiopental sodium or ketamine HCl, and maintenance with halothane or isoflurane inhalation anaesthetics.
Sedivet® has also been used successfully with the analgaesic butorphanol.
Sedivet® should not be used in breeding horses since the potential risk has not been evaluated in either mares or stallions.
Do not use in horses with pre-existing AV block, respiratory disease, advanced liver or kidney disease or endotoxic or traumatic shock.
As with other alpha-2-sympathomimetics, horses under sedation with Sedivet® may demonstrate increased skin sensitivity of the hind limbs. Some horses, although apparently sedated, may still respond to external stimuli. Practitioners and handlers should use caution and appropriate handling techniques to avoid injury.
Following treatment, occasional sweating and diuresis may be seen as well as ataxia, transitory hypertension followed by hypotension and bradycardia. These conditions, if present, should be monitored.
This drug is not to be used in horses that are to be slaughtered for use in food.
20 mL multidose vials.
Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4
NAC No.: 12300332
5180 SOUTH SERVICE ROAD, BURLINGTON, ON, L7L 5H4
|Customer Care No.:||800-567-1885|
|Technical Services No.:||1-877-565-5501|
|Every effort has been made to ensure the accuracy of the Sedivet information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-02-06